Physician profile
Robin R Vann
NPI 1679660054
$212,628.26
in general payments reported to CMS, 2019-2025
7 companies · $42K in 2025
The $42K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $22K · 2021: $28K · 2022: $26K · 2023: $22K · 2024: $33K · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $82K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,500 · Travel and Lodging: $5,174 · Food and Beverage: $3,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $82,315.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,500.00 |
| Travel and Lodging | $5,173.66 |
| Food and Beverage | $3,011.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $131,536.66 | 2019-2025 | Argos, Lensx, Acrysof Iq Panoptix Uv Iol |
| Alcon Research LLC | $77,509.77 | 2019-2025 | Unity, Air Optix |
| Ocular Therapeutix, INC. | $3,262.73 | 2019-2022 | |
| Quidel Corporation | $213.52 | 2019 | |
| Bausch & Lomb Americas INC. | $38.79 | 2025 | Envista Envy Iol |
| Carl Zeiss Meditec, INC. | $36.11 | 2023 | |
| Tearlab Corp | $30.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Vann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.